- Home
- UPST vs LEGN Comparison
UPST vs LEGN Comparison
Compare UPST & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- LEGN
- Stock Information
- Founded
- UPST 2012
- LEGN 2014
- Country
- UPST United States
- LEGN United States
- Employees
- UPST N/A
- LEGN N/A
- Industry
- UPST Finance: Consumer Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- LEGN Health Care
- Exchange
- UPST Nasdaq
- LEGN Nasdaq
- Market Cap
- UPST 6.6B
- LEGN 7.0B
- IPO Year
- UPST 2020
- LEGN 2020
- Fundamental
- Price
- UPST $46.00
- LEGN $31.52
- Analyst Decision
- UPST Buy
- LEGN Strong Buy
- Analyst Count
- UPST 14
- LEGN 12
- Target Price
- UPST $77.08
- LEGN $79.00
- AVG Volume (30 Days)
- UPST 4.7M
- LEGN 1.1M
- Earning Date
- UPST 05-06-2025
- LEGN 03-11-2025
- Dividend Yield
- UPST N/A
- LEGN N/A
- EPS Growth
- UPST N/A
- LEGN N/A
- EPS
- UPST N/A
- LEGN N/A
- Revenue
- UPST $676,961,000.00
- LEGN $627,241,000.00
- Revenue This Year
- UPST $50.82
- LEGN $66.76
- Revenue Next Year
- UPST $22.62
- LEGN $51.82
- P/E Ratio
- UPST N/A
- LEGN N/A
- Revenue Growth
- UPST 23.43
- LEGN 119.97
- 52 Week Low
- UPST $20.60
- LEGN $30.17
- 52 Week High
- UPST $96.43
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- UPST 36.09
- LEGN 32.16
- Support Level
- UPST $43.24
- LEGN $34.00
- Resistance Level
- UPST $56.10
- LEGN $36.20
- Average True Range (ATR)
- UPST 3.06
- LEGN 1.51
- MACD
- UPST 0.11
- LEGN -0.51
- Stochastic Oscillator
- UPST 21.48
- LEGN 1.76
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.